← Regulatory Atlas

Planning · K260322

Acorn 3D Software (AC-SEG-4009); Acorn 3DP Model (AC-101-XX)

A spine-planning suite whose newest clearance concerns correction simulation while its machine-learning segmentation and PCCP come from earlier submissions.

Mighty Oak Medical

Pathway
Traditional 510(k)
Decision
Jun 11, 2026
Product code
QIH
Evidence
Nonclinical
First published
Sep 9, 2026
Page updated
Sep 17, 2026
Evidence search
Sep 8, 2026
Professional review
Not claimed

Anonymous editorial source review; independent regulatory, legal, or professional peer review is not claimed. Page updates do not reset evidence dates.

What FDA established

FDA accepted additional alignment, measurement and correction-simulation functions while retaining the previously cleared locked ML segmentation and its inherited PCCP.

What FDA did not establish

It does not prove better correction, fewer complications, autonomous planning or a newly authorized adaptive model in K260322.

Authorization

K260322 added anatomy alignment, measurements and correction simulation; it did not introduce a new ML segmentation model or modify the inherited PCCP.

Submission lineageK260322 → K252103 → K234009 PCCP.

Intended use

Visualize and segment medical images, align anatomy, measure spinopelvic geometry, plan pedicle screw placement, simulate correction and produce digital or physical three-dimensional models.

Input
CT, synthetic CT or CTA DICOM imaging; User-defined reference geometry and surgical correction inputs
Output
Editable vertebral and sacral segmentations; Aligned anatomy and spinopelvic measurements; Thoracic and lumbar pedicle-screw trajectories; Simulated correction plans and exportable three-dimensional models
Use boundary
Outputs require expert clinical judgment and user review; the software does not autonomously select or execute a surgical correction.

AI disclosure and function

AI/ML explicit

The suite retains a 3D U-Net machine-learning model for automatic vertebral and sacral segmentation; the newly added Correction module is algorithmic planning and simulation rather than a newly trained AI model.

No ML algorithm improvement or PCCP change occurred in K260322; the applicable segmentation PCCP was authorized in K234009 and carried through prior submissions.

No foundation-model, LLM, or generative-AI function was identified in the reviewed FDA materials.

Validation

Software verification, end-user validation and bench testing of the new Correction module, including simulated plans against surgeon-defined angular targets and intra- and inter-observer variability.

Comparator
The K252103 predicate suite and surgeon-defined correction inputs with predefined angular acceptance criteria.
Ground truth
Surgeon-defined target angular metrics and repeat measurements used as nonclinical reference values.
Representation
Not applicable to the reported bench and end-user testing for the new module; no new patient cohort was described for K260322.

Reported performance

Target angular accuracy
within 3 degreesBench accuracy of simulated correction against surgeon-defined inputs, not achieved postoperative alignment.
Intra- and inter-observer variability
less than 3 degrees by mean absolute difference and 2×SDRepeatability of simulated planning observations, not clinical-outcome consistency.

Limitations

  • The new submission primarily validates correction simulation through bench and end-user testing.
  • No patient-level deformity correction, reoperation or neurological-outcome evidence was reported.
  • The ML segmentation evidence and PCCP originate from earlier submissions rather than a new model change in K260322.

It does not prove better correction, fewer complications, autonomous planning or a newly authorized adaptive model in K260322.

PCCP / Change control

Inherited from K234009; the indexed submission itself shows a “No” database flag. Controlled future updates to machine-learning segmentation of bony anatomy under the K234009 protocol; released algorithms remain trained, tuned and locked.

  • Train, tune and lock each modified algorithm before release
  • Assess changes against defined technical and performance specifications
  • Mitigate degradation in segmentation performance within unchanged indications

A PCCP authorizes bounded changes under predefined controls. It is not permission for unrestricted or continuously self-learning behavior.

Postmarket check

No exact-name openFDA device-enforcement result was found in the targeted query.

No exact-name openFDA result found as of 2026-09-08; this is not proof that no recall exists.

Primary FDA sources

  1. FDA AI-enabled device list — Submission K260322Confirms inclusion, list display name, company, lead panel, product code and decision date only.
  2. FDA submission database — 510(k) K260322Confirms pathway, review panel, decision, primary and subsequent product codes, and No PCCP database flag.
  3. FDA decision summary — 510(k) summary pp. 1-8; performance p. 4; AI and PCCP lineage pp. 7-8Supports intended use, predicates, current module changes, bench results, ML segmentation description and inherited PCCP lineage.

Sources checked Sep 8, 2026 · Next scheduled review Oct 8, 2026. “No exact-name result” is a bounded search finding, not proof that no safety event or recall exists.